{"presentation":{"slides":[{"elements":[{"x":4.357298474945534,"y":4.29436559139785,"width":88.23529411764706,"height":79.56989247311827,"action":{"library":"H5P.AdvancedText 1.1","params":{"text":"

There is no evidence of a significant association between the development of resistance to H or R and the use of these drugs for TPT.<\/li>\n\t
A very small proportion of people on TPT develop serious adverse events<\/li>\n\t
Most adverse events are self-limiting and reversible<\/li>\n\t
Shorter rifamycin-based regimens have a better safety profile <\/li>\n\t
TB disease must be ruled out before TPT is initiated. <\/li>\n\t
Regular follow-up to rule out development of active TB disease. <\/li>\n\t
Rapid molecular DST must be offered to all patients if TB disease is detected before, during or any time post-TPT.<\/li>\n<\/ul>\n"},"subContentId":"072ca982-7bf5-497c-83d9-0640324b3d8e","metadata":{"contentType":"Text","license":"U","title":"Untitled Text"}},"alwaysDisplayComments":false,"backgroundOpacity":0,"displayAsButton":false,"buttonSize":"big","goToSlideType":"specified","invisible":false,"solution":""}],"slideBackgroundSelector":{}},{"elements":[{"x":3.2679738562091507,"y":6.438172043010752,"width":90.41394335511983,"height":77.41935483870967,"action":{"library":"H5P.AdvancedText 1.1","params":{"text":"
TPT is relatively safe (systematic review 2018)<\/strong><\/p>\n\n

Search

Emergence of drug resistance following TPT

Content Status

Type

Linked Node

Emergence of drug resistance following TPT

Content Creator

Reviewer